ITGAM and non-small cell lung carcinoma: In advanced NSCLC patients treated with Atezolizumab, disease control was associated with decreased frequencies of Tregs and Lin−HLA-DR−CD33+CD11b+ MDSCs and a reduction in NLR after treatment (101).